BUD28 Antibody

What is CD28 and why is it an important target for therapeutic antibodies?

CD28 is a critical costimulatory receptor primarily expressed on T cells that provides the "second signal" required for complete T-cell activation following antigen recognition. In the absence of CD28 costimulation, T cells typically experience insufficient activation and early exhaustion, limiting their effectiveness in immune responses . CD28 has emerged as a valuable therapeutic target because modulating its signaling pathway can significantly impact T-cell function in various diseases, particularly in cancer immunotherapy where enhanced T-cell activation can promote tumor cell killing .

The importance of CD28 targeting stems from its ability to synergize with CD3 signaling. While CD3 bispecific T-cell engagers can activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies, the addition of CD28 costimulatory signals significantly boosts T-cell activity and longevity . This combinatorial approach offers an attractive strategy to enhance immunotherapeutic efficacy beyond what either target alone could achieve .

What distinguishes superagonistic from non-superagonistic anti-CD28 antibodies?

Superagonistic anti-CD28 antibodies, such as TGN1412, can activate T cells independently of T-cell receptor (TCR) stimulation by binding to a lateral epitope on CD28, leading to robust T-cell activation without antigen specificity . This unrestricted activation can trigger massive cytokine release and severe inflammatory responses, as tragically demonstrated in TeGenero's 2006 Phase 1 clinical trial where TGN1412 caused life-threatening cytokine release syndrome in healthy volunteers .

In contrast, non-superagonistic anti-CD28 antibodies like E1P2 bind to conformational epitopes near the apex of CD28, similar to its natural ligands (CD80/CD86) . This binding specificity ensures that T-cell activation remains dependent on concurrent TCR stimulation, preventing uncontrolled immune responses. The epitope binding location is critical—E1P2's binding near the apex of CD28 rather than the lateral surface explains its lack of superagonistic activity in both in vitro studies with human peripheral blood mononuclear cells (PBMCs) and in vivo safety evaluations in humanized NSG mice .

How do US28 antibodies differ from CD28 antibodies in terms of research applications?

While CD28 antibodies target a human T-cell costimulatory receptor involved in immune activation, US28 antibodies target a chemokine receptor encoded by human cytomegalovirus (HCMV) . This fundamental difference drives their distinct research applications.

CD28 antibodies are primarily used in immunotherapy research, T-cell activation studies, and investigations of costimulatory signaling pathways . They serve both as research tools to understand T-cell biology and as therapeutic candidates for cancer and autoimmune disease interventions .

In contrast, US28 antibodies are primarily employed in virology research focusing on cytomegalovirus infections . They enable the detection and study of viral proteins in infected cells through applications including Western blotting, ELISA, immunocytochemistry, and immunofluorescence microscopy . Some specialized US28 antibodies, such as nanobodies and recombinant single-domain antibodies, offer unique capabilities for targeting this viral receptor in both research and potential therapeutic applications .

What technologies are used to develop highly specific anti-CD28 antibodies with reduced risk of superagonism?

The development of safe, non-superagonistic anti-CD28 antibodies employs several advanced technologies:

Phage display technology has proven particularly valuable, as demonstrated in the development of E1P2 . This approach allows for the screening of vast antibody libraries against specific CD28 epitopes, enabling the selection of variants with desired binding characteristics while avoiding those with superagonistic properties . The technique involves displaying antibody fragments on bacteriophage surfaces, followed by selective enrichment through multiple rounds of binding to the target protein .

Epitope mapping is critical for characterizing antibody binding sites and predicting functional outcomes . Techniques such as X-ray crystallography, hydrogen-deuterium exchange mass spectrometry, and mutagenesis studies help determine whether an antibody binds near the apex of CD28 (like natural ligands) or at lateral sites associated with superagonism .

Biophysics-informed computational modeling has emerged as a powerful approach for predicting and designing antibody specificity . These models, trained on data from experimental antibody selections, can identify binding modes associated with specific ligands and generate novel antibody variants with customized binding profiles . This approach combines machine learning with biophysical principles to navigate the complex landscape of antibody-antigen interactions .

Safety assessment protocols have been developed specifically for CD28-targeting antibodies, including in vitro cytokine release assays using human PBMCs and in vivo studies in humanized mouse models that can predict potential adverse reactions before clinical testing .

What methodological approaches are most effective for evaluating anti-CD28 antibody specificity and functionality?

A comprehensive evaluation of anti-CD28 antibody specificity and functionality requires multiple complementary methodologies:

Flow cytometry using primary human and mouse T-cells provides crucial data on binding specificity, allowing researchers to confirm target engagement and cross-species reactivity . This technique can verify whether an antibody binds to CD28 on relevant cell populations and can help quantify expression levels on different cell subsets .

In vitro T-cell activation assays using human PBMCs are essential for distinguishing between superagonistic and non-superagonistic activities . These assays typically measure cytokine production, T-cell proliferation, and activation marker expression in response to the antibody alone or in combination with TCR stimulation . A superagonistic antibody will induce robust activation without TCR engagement, while a non-superagonistic antibody will not .

For combinatorial approaches, co-culture systems with tumor cells, T cells, and bispecific antibodies can assess how anti-CD28 antibodies enhance the cytotoxic activity of T-cell engagers . Key readouts include tumor cell killing efficiency, T-cell proliferation rates, and cytokine production profiles .

Humanized mouse models provide critical in vivo safety and efficacy data . NSG (NOD scid gamma) mice engrafted with human immune cells offer a valuable system for evaluating potential cytokine release syndrome and other adverse effects before clinical testing . The absence of cytokine storms in these models after anti-CD28 antibody administration provides important safety indicators .

How should researchers design selection protocols for phage display to generate antibodies with precise binding specificity?

Effective phage display selection for antibodies with precise binding specificity requires careful protocol design:

Multiple selection strategies should be employed simultaneously, including positive selection against the desired target and negative selection against closely related molecules or epitopes that should be avoided . This parallel approach increases the likelihood of isolating antibodies with the desired specificity profile .

Sequential rounds of selection with increasing stringency can progressively enrich for high-affinity binders . Typically, two to four rounds of selection are performed, with amplification steps between rounds to expand selected phage populations . Each round should incorporate appropriate negative selection steps to eliminate unwanted cross-reactivity .

Researchers should systematically collect phages at each step of the protocol to closely monitor antibody library composition evolution . This tracking helps identify when selection has converged and provides valuable datasets for computational modeling of binding specificities .

For developing antibodies with custom specificity profiles, combinations of ligands can be used in selection experiments . For example, selections against various combinations of ligands (individually and in mixtures) can provide training sets for computational models that identify binding modes associated with each specific ligand .

Post-selection characterization should employ multiple orthogonal methods to confirm binding specificity, including ELISA, surface plasmon resonance, and functional assays specific to the intended application .

How does selective CD28 blockade compare to CTLA-4-Ig in preventing alloantibody responses in transplantation?

Selective CD28 blockade demonstrates superior efficacy in preventing alloantibody responses compared to CTLA-4-Ig (belatacept) through several distinct mechanisms:

CD28-specific domain antibodies (dAbs) provide more potent inhibition of follicular T helper (Tfh) cell responses than CTLA-4-Ig . Since Tfh cells are critical orchestrators of germinal center reactions and B cell maturation, their more effective suppression translates to greater inhibition of donor-specific antibody (DSA) formation .

Selective CD28 blockade preserves CTLA-4 coinhibitory signaling, whereas CTLA-4-Ig blocks both CD28 and CTLA-4 interactions with their ligands . This preservation of CTLA-4 function is a key advantage, as demonstrated by experiments showing that adding CTLA-4-blocking antibodies to anti-CD28 dAb treatment reversed the inhibitory effects on alloantibody formation .

Examination of B cell subsets revealed that anti-CD28 dAb treatment more effectively inhibits germinal center B cell (GL7+CD95+) and antibody-secreting cell (ASC) responses compared to CTLA-4-Ig . This superior inhibition of B cell differentiation and antibody production pathways directly contributes to reduced DSA levels .

In transplantation models, selective CD28 blockade has demonstrated complete inhibition of DSA in recipients of allogeneic skin grafts, whereas CTLA-4-Ig showed less consistent inhibition . This enhanced efficacy suggests that selective CD28 blockade may be particularly valuable for transplant recipients at high risk for antibody-mediated rejection .

What are the challenges in developing bispecific antibodies that combine CD28 costimulation with CD3 engagement?

Developing bispecific antibodies that combine CD28 costimulation with CD3 engagement presents several complex challenges:

Fine-tuning the relative binding affinities for CD28 and CD3 is critical to achieve optimal T-cell activation without triggering cytokine release syndrome . If the CD28 engagement is too strong or occurs independently of CD3 signaling, it may lead to superagonistic effects and dangerous cytokine storms . Conversely, if it's too weak, the costimulatory benefit may be lost.

Epitope selection for both targets must be carefully considered, as the binding site on CD28 significantly impacts functional outcomes . Targeting the apex rather than lateral epitopes of CD28 helps avoid superagonistic activity, but must be engineered precisely within the bispecific format .

Manufacturing consistency presents technical challenges, as bispecific antibodies often require specialized production and purification processes to ensure correct chain pairing and consistent quality . These manufacturing considerations become particularly important when transitioning from research to clinical development.

Clinical translation requires extensive preclinical safety evaluation, particularly given the historical concerns with superagonistic anti-CD28 antibodies . Testing must verify that the bispecific approach delivers localized T-cell activation only at target sites (e.g., tumors) without systemic immune hyperactivation .

What strategies can minimize cytokine release syndrome risk when developing CD28-targeting therapeutic antibodies?

Multiple strategies have been developed to minimize cytokine release syndrome (CRS) risk in CD28-targeting therapeutics:

Epitope selection is perhaps the most critical factor, as demonstrated by E1P2's design . By targeting conformational epitopes near the apex of CD28 (similar to natural ligands) rather than the lateral epitopes bound by superagonistic antibodies like TGN1412, researchers can develop antibodies that require concurrent TCR stimulation for T-cell activation . This requirement prevents the systemic, TCR-independent T-cell activation that triggers CRS .

Fc engineering can further reduce CRS risk by modifying or eliminating Fc-mediated functions . Antibody formats like domain antibodies (dAbs), which lack Fc regions entirely, or engineered IgGs with mutations that prevent FcγR binding, can minimize unwanted Fc-mediated crosslinking of CD28 receptors that might contribute to superagonistic activity .

Comprehensive in vitro screening using human PBMCs from multiple donors is essential for identifying potential superagonistic activity before advancing to in vivo studies . These assays should measure multiple cytokines (particularly IL-2, IL-6, TNF-α, and IFN-γ) and be conducted using various antibody concentrations to detect any dose-dependent superagonistic effects .

Humanized mouse models provide a critical in vivo safety assessment . NSG mice engrafted with human immune cells offer a valuable system for detecting potential CRS before clinical testing, as demonstrated in comparative studies of E1P2 versus TGN1412 . The absence of cytokine storms in these models provides important safety indicators .

Conditional activation approaches, such as bispecific antibodies that engage CD28 only in the presence of tumor antigens, can spatially restrict CD28 costimulation to the tumor microenvironment, reducing the risk of systemic immune activation .

How does the combination of CD3 and CD28 targeting enhance cancer immunotherapy efficacy compared to CD3 targeting alone?

The combination of CD3 and CD28 targeting offers several significant advantages over CD3 targeting alone in cancer immunotherapy:

Enhanced T-cell activation and proliferation represents the primary benefit of this combinatorial approach . While CD3 bispecific T-cell engagers can activate cytotoxic T-cells, the absence of costimulatory signaling through CD28 typically leads to suboptimal activation and early exhaustion . Adding CD28 costimulation provides the "second signal" needed for complete T-cell activation, driving superior proliferation and sustained effector function .

In vitro activity assays using human PBMCs have demonstrated that combining E1P2 (anti-CD28) with CD3 bispecific antibodies significantly enhances tumor cell killing compared to CD3 bispecifics alone . This improved cytotoxicity directly translates to greater anti-tumor efficacy .

T-cell persistence and memory formation are enhanced by CD28 costimulation, which upregulates anti-apoptotic proteins and promotes metabolic reprogramming toward a more sustainable state . This promotes long-term immunosurveillance and potentially reduces the risk of tumor recurrence .

Resistance to T-cell exhaustion is another crucial advantage, as CD28 signaling counteracts the upregulation of inhibitory receptors like PD-1 and maintains T-cell functionality in the immunosuppressive tumor microenvironment . This resistance to exhaustion is particularly valuable for solid tumors, where T-cell dysfunction is a major limitation of current immunotherapies .

The "three-signal" paradigm of T-cell activation suggests that optimal anti-tumor immunity requires antigen recognition (signal 1), costimulation (signal 2), and inflammatory cytokines (signal 3) . By addressing the first two signals with CD3 and CD28 targeting, this approach creates a more robust foundation for effective cancer immunotherapy .

What are the applications of US28 antibodies in antiviral research and potential therapeutic development?

US28 antibodies have several specialized applications in antiviral research and therapeutic development:

Detection and quantification of viral infection is a fundamental application, as US28 antibodies enable researchers to identify HCMV-infected cells through techniques including Western blotting, ELISA, immunocytochemistry, and immunofluorescence . This capability is crucial for studying viral pathogenesis and evaluating potential antiviral interventions .

Specialized formats like nanobodies and recombinant single-domain antibodies against US28 offer unique advantages for certain applications . These smaller antibody fragments can access epitopes that might be sterically hindered for conventional antibodies and may provide better tissue penetration in both research and therapeutic contexts .

Neutralization studies employ anti-US28 antibodies to block the function of this viral GPCR, which plays multiple roles in HCMV pathogenesis including viral dissemination, immune evasion, and potentially oncogenesis . Antibodies with neutralizing activity (indicated by "Neut" applications in product listings) can help elucidate the contribution of US28 to viral pathogenesis and may serve as leads for therapeutic development .

Structure-function studies benefit from antibodies that recognize specific domains or conformational states of US28 . These tools help researchers understand how US28 interacts with human chemokines and mediates signaling that benefits viral persistence .

Diverse research applications are supported by the wide range of US28 antibodies available with different conjugates (including unconjugated, biotin, FITC, HRP, and Alexa dyes), enabling multiparameter analyses in complex experimental systems .

How can integrated experimental-computational approaches accelerate the development of antibodies with custom specificity profiles?

Integrated experimental-computational approaches offer a powerful paradigm for accelerating antibody development:

The combination of high-throughput selection experiments with computational modeling creates a synergistic framework where experimental data trains models that can then guide subsequent experiments . This iterative process becomes increasingly efficient as the models improve with additional data .

For generating antibodies with custom specificity profiles, computational models can optimize energy functions associated with different binding modes . To create cross-specific antibodies that interact with several distinct ligands, the models jointly minimize the energy functions associated with the desired targets . Conversely, to generate highly specific antibodies, the models minimize the energy function for the desired ligand while maximizing those for undesired ligands .

Phage display experiments provide rich datasets for model training when designed to include selections against diverse combinations of related ligands . By systematically collecting phages at each step of the protocol, researchers can closely monitor the antibody library composition evolution and generate comprehensive training data .

The predictive power of biophysics-informed models extends beyond the sequences present in the initial library, enabling the generation of entirely novel antibody variants with predefined binding characteristics . This capability dramatically expands the accessible sequence space compared to traditional selection methods .

This integrated approach has successfully predicted outcomes for experiments involving new combinations of ligands and generated antibody variants with customized specificity profiles not present in the training data . These successes demonstrate the practical utility of combining experimental and computational methods for antibody engineering .

What new approaches are being developed to enhance the safety profile of CD28-targeting therapies while maintaining efficacy?

Several innovative approaches are being explored to enhance safety while maintaining efficacy:

Conditional activation strategies are being developed to ensure CD28 engagement occurs only in specific microenvironments or in the presence of certain disease markers . These include tumor-targeted bispecific antibodies that co-engage CD28 only on T cells that have recognized tumor antigens, spatially restricting costimulation to the tumor site .

Precise epitope targeting remains a cornerstone of safety enhancement, with continued refinement of antibodies that bind CD28 in ways that preclude superagonistic activity . E1P2's development demonstrates how conformational epitope mapping and structure-guided design can yield antibodies that provide costimulation without superagonism .

Tunable costimulation approaches aim to provide "just enough" CD28 signaling to enhance T-cell function without triggering cytokine storms . This includes engineering antibodies with carefully calibrated binding affinities and exploring partial agonists that deliver moderated CD28 signaling .

Selective CD28 blockade strategies differ from agonistic approaches by blocking CD28 interactions with its natural ligands while preserving CTLA-4 coinhibitory capacity . This selective blockade has shown superior immunosuppressive effects compared to agents like CTLA-4-Ig that block both pathways, particularly in preventing alloantibody responses in transplantation contexts .

Combination therapies that incorporate CD28-targeting antibodies with other immunomodulatory agents are being explored to achieve synergistic effects with improved safety profiles . These combinatorial approaches may allow for lower doses of each agent, reducing the risk of adverse effects while maintaining therapeutic benefit .

What emerging technologies might enable better prediction and prevention of adverse immune reactions to therapeutic antibodies?

Emerging technologies are transforming our ability to predict and prevent adverse immune reactions:

Advanced humanized mouse models with increasingly sophisticated human immune components provide more predictive preclinical safety assessments . These include models containing human lymphoid tissues, human HLA molecules, and multiple human immune cell lineages, offering more faithful recapitulation of human immune responses to therapeutic antibodies .

Organ-on-chip and microphysiological systems recreate human tissue microenvironments for evaluating antibody effects under more physiologically relevant conditions than traditional cell culture . These systems can incorporate multiple cell types and dynamic flow conditions, providing insights into tissue-specific responses that might not be evident in conventional assays .

High-dimensional single-cell analysis technologies, including single-cell RNA sequencing, CyTOF, and spectral flow cytometry, enable comprehensive profiling of immune cell responses to therapeutic antibodies at unprecedented resolution . These technologies can identify rare cell populations and subtle phenotypic changes that might presage adverse reactions .

Machine learning algorithms trained on large datasets of antibody sequences, structures, and clinical outcomes are improving our ability to predict immunogenicity and other adverse effects . These computational approaches can identify subtle patterns in antibody features that correlate with safety profiles, guiding the design of safer therapeutics .

Systems immunology approaches that integrate multiple data types (genomic, proteomic, metabolomic, etc.) are providing holistic views of how therapeutic antibodies perturb immune networks . This comprehensive understanding helps identify potential off-target effects and pathway-level perturbations that might lead to adverse reactions .